NLRP3 and cryopyrin-associated periodic syndrome: Current clinical trials evaluating pharmacological interventions to mitigate NLRP3 inflammasome activation have been designed in CAPS patients to counteract this gain-of-function (tranilast NCT03923140, canakinumab NCT01576367, or rilonacept NCT00288704), rather than its malfunction, leading to autoimmune or inflammatory diseases.